Agilus Diagnostics

Overview

Agilus Diagnostics is an Indian diagnostic testing company previously known as SRL Diagnostics. Part of the Fortis Healthcare group, it provides pathology services that help clinicians investigate symptoms, diagnose disease and monitor treatment. Its offering encompasses routine blood and urine tests alongside more specialised laboratory investigations. Although listed within the broader health and senior care sector, it is a diagnostics business rather than a provider of residential care or home-based personal support.

For prospective franchisees, the important distinction is between the company's testing infrastructure and its patient-facing collection network. A branded collection centre receives patients and collects specimens for processing within the laboratory network. It should not be assumed to perform the tests on site or to offer the capabilities of a full diagnostic laboratory.

History and growth

The business traces its origins to 1995 and built its national profile under the SRL name. Its development reflected the expansion of organised private diagnostics in India, where large networks compete with hospital laboratories, regional operators and independent pathology practices. Growth involved extending laboratory capacity and establishing more places where patients could access testing without travelling to a central laboratory.

SRL Diagnostics adopted the Agilus Diagnostics name in 2023. The change introduced a new corporate identity for an established operating business, rather than marking the creation of a new diagnostic network. Its relationship with Fortis Healthcare is also an important part of the corporate background. Prospective partners should nevertheless assess the specific contracting company and operating arrangements offered to them, rather than treating group affiliation as a substitute for examining the proposed agreement.

Global footprint

India is the core market. Company reporting for the financial year ended March 2024 described a network of around 400 laboratories, supported by a much broader collection network. These are different measures: laboratories process specimens, while collection centres and other patient access points connect patients with that infrastructure. The laboratory figure is therefore not a count of available franchises or independently owned outlets.

Agilus has also reported an international presence, but overseas laboratories, partnerships and service relationships should not be treated as interchangeable forms of operation. A single country total can obscure those differences. For an Indian franchise applicant, the more useful geographic questions concern the nearest processing laboratory, specimen transport coverage and the company's existing local collection network. National scale does not by itself establish whether a particular neighbourhood is adequately served.

How the franchise model works

Agilus promotes partnership opportunities involving branded diagnostic sample collection centres. In this format, the local operator provides a patient-facing location, while collected specimens enter the wider testing network. The centre's work can include patient registration, booking, sample collection, payment handling and helping patients obtain reports. The precise division of responsibilities must be established through the company's current partnership documentation.

The commercial proposition depends on connecting local patient demand with centralised laboratory capability. A collection centre generally has a different equipment and staffing profile from a laboratory, but it still carries important operational responsibilities. Correct patient identification, specimen labelling, storage and timely transport all affect service quality. Applicants should confirm who supplies consumables, recruits or approves staff, arranges sample pickups and manages complaints. Home collection should only be included in a business plan where the proposed agreement explicitly supports it.

Investment and requirements

A standard, current Agilus franchise fee and all-inclusive investment range are not publicly disclosed in a form that can be applied reliably across locations. Figures published on third-party franchise websites should not be treated as a confirmed company quotation. Prospective franchisees should request the franchise disclosure documents, where available or applicable, together with the proposed agreement and a detailed written schedule of costs.

The budget needs to distinguish initial expenditure from ongoing operating costs. Relevant items may include premises, fit-out, collection equipment, information technology, staff, consumables, waste management and working capital. Applicants should establish which costs sit with the partner and which services the company provides. Published network size says little about the likely income of an individual centre. Revenue sharing, test prices, discounts, settlement periods and responsibility for repeat collections need specific clarification before projected returns can be assessed.

What franchisees should consider

Location assessment should consider nearby clinics, residential catchments, accessibility and competing collection centres, rather than relying solely on pedestrian traffic. Equally important is the logistics chain between the centre and its supporting laboratory. Pickup frequency, temperature control, sample acceptance rules and arrangements for urgent or specialised tests influence the service patients actually receive.

Healthcare operations also require more than ordinary retail discipline. Applicants need to establish the applicable local registrations, staffing qualifications, infection-control procedures, biomedical waste arrangements and patient-data safeguards. Accreditation must be understood at the level of the relevant laboratory and its accredited testing scope; a network association is not a blanket assurance covering every activity. Other practical questions include territory protection, company-operated home collection nearby, access to booking systems, report delivery, renewal terms and the process for ending the relationship.

Competitive landscape

Agilus competes with established Indian diagnostic networks including Dr Lal PathLabs, Metropolis Healthcare and Thyrocare. Hospital laboratories, independent local laboratories and regional chains also shape competition. These businesses differ in their geographic strengths, testing mix, collection arrangements and approach to consumer pricing, making national brand comparisons only a starting point.

At neighbourhood level, patients and referring clinicians may weigh convenience, turnaround times, perceived reliability and familiarity alongside price. Online booking and home sample collection further widen the competitive field beyond nearby shopfronts. A prospective Agilus partner therefore needs to examine both physical competitors and services reaching the same catchment through digital channels.

Outlook

Chronic disease monitoring, preventive testing and demand for accessible healthcare provide an established role for organised diagnostics. However, competition on price, service expectations and the operational demands of handling specimens can constrain individual collection centres. Agilus offers the background of an established testing network; the viability of a partnership still depends on local demand, clear contractual responsibilities and consistently executed patient service.